| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/HP.2011.10.920 |
| P698 | PubMed publication ID | 22056821 |
| P50 | author | Gilles Lemesle | Q56973448 |
| P2093 | author name string | Cedric Delhaye | |
| Laurent Bonello | |||
| Jean-Marc Lablanche | |||
| Francesco Paparoni | |||
| P2860 | cites work | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study | Q28165412 |
| Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents | Q28174787 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up | Q28199661 | ||
| Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation | Q28200400 | ||
| A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization | Q28202763 | ||
| Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial | Q28211092 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment | Q28219004 | ||
| Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization | Q28222382 | ||
| A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease | Q28238811 | ||
| Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology | Q28239975 | ||
| Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation | Q28277375 | ||
| Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern | Q28291903 | ||
| ??? | Q28298419 | ||
| Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). | Q33377713 | ||
| Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents | Q33451111 | ||
| Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology | Q35628214 | ||
| Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis | Q36614252 | ||
| Stent thrombosis in 2008: definition, predictors, prognosis and treatment. | Q37342305 | ||
| Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. | Q37415874 | ||
| Drug-eluting stents: issues of late stent thrombosis | Q37644702 | ||
| Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. | Q37752222 | ||
| Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry | Q39986890 | ||
| Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co | Q42781499 | ||
| Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet trea | Q42795434 | ||
| Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation | Q42908804 | ||
| Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial | Q42917584 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Duration of dual antiplatelet therapy after implantation of drug-eluting stents. | Q43128835 | ||
| Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt | Q43128838 | ||
| A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment | Q43163642 | ||
| Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement | Q43234546 | ||
| Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials | Q44964313 | ||
| The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease | Q45214743 | ||
| Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome | Q45280954 | ||
| Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. | Q45930222 | ||
| Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months | Q46068909 | ||
| Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation | Q46127806 | ||
| Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. | Q46209759 | ||
| Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality | Q46305695 | ||
| Unplanned surgery after drug eluting stent implantation: a strategy for safe temporary withdrawal of dual oral antiplatelet therapy | Q46547008 | ||
| Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). | Q46714815 | ||
| Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome | Q46770154 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. | Q47330327 | ||
| 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200 | Q50577270 | ||
| Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. | Q51093369 | ||
| Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. | Q51136385 | ||
| Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. | Q51170005 | ||
| Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. | Q51182242 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 32-40 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Hospital Practice | Q5908551 |
| P1476 | title | Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature | |
| P478 | volume | 39 |
| Q33936118 | Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease | cites work | P2860 |
Search more.